HPS has been shown to have potential in treating NAFLD by lowering LDL-C, AST, ALT, and SREBP-1c levels while increasing HDL-C, SOD-1, phosphorylated AMP, and AMPK-α levels. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.